Literature DB >> 28662774

Current advances in endocrine therapy options for premenopausal women with hormone receptor positive breast cancer.

Mary L Gemignani1, David J Hetzel2.   

Abstract

Entities:  

Keywords:  Breast cancer; Endocrine therapy; Hormone receptor

Mesh：

Substances：

Year:  2017        PMID： 28662774      PMCID： PMC5639942          DOI： 10.1016/j.ygyno.2017.06.023

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN： 0090-8258            Impact factor:   5.482


× No keyword cloud information.
  18 in total

1.  Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer.

Authors:  Mitch Dowsett; Per E Lønning; Nancy E Davidson
Journal:  J Clin Oncol       Date:  2016-01-04       Impact factor: 44.544

2.  Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.

Authors:  A S Coates; E P Winer; A Goldhirsch; R D Gelber; M Gnant; M Piccart-Gebhart; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2015-05-04       Impact factor: 32.976

3.  Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.

Authors:  Jürg Bernhard; Weixiu Luo; Karin Ribi; Marco Colleoni; Harold J Burstein; Carlo Tondini; Graziella Pinotti; Simon Spazzapan; Thomas Ruhstaller; Fabio Puglisi; Lorenzo Pavesi; Vani Parmar; Meredith M Regan; Olivia Pagani; Gini F Fleming; Prudence A Francis; Karen N Price; Alan S Coates; Richard D Gelber; Aron Goldhirsch; Barbara A Walley
Journal:  Lancet Oncol       Date:  2015-06-16       Impact factor: 41.316

4.  Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.

Authors:  Kelly Metcalfe; Henry T Lynch; William D Foulkes; Nadine Tung; Charmaine Kim-Sing; Olufunmilayo I Olopade; Andrea Eisen; Barry Rosen; Carrie Snyder; Shelley Gershman; Ping Sun; Steven A Narod
Journal:  JAMA Oncol       Date:  2015-06       Impact factor: 31.777

5.  Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study--NCIC CTG MA.5.

Authors:  Wendy R Parulekar; Andrew G Day; Jon A Ottaway; Lois E Shepherd; Maureen E Trudeau; Vivien Bramwell; Mark Levine; Kathleen I Pritchard
Journal:  J Clin Oncol       Date:  2005-09-01       Impact factor: 44.544

6.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

7.  Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

Authors:  Olivia Pagani; Meredith M Regan; Barbara A Walley; Gini F Fleming; Marco Colleoni; István Láng; Henry L Gomez; Carlo Tondini; Harold J Burstein; Edith A Perez; Eva Ciruelos; Vered Stearns; Hervé R Bonnefoi; Silvana Martino; Charles E Geyer; Graziella Pinotti; Fabio Puglisi; Diana Crivellari; Thomas Ruhstaller; Eric P Winer; Manuela Rabaglio-Poretti; Rudolf Maibach; Barbara Ruepp; Anita Giobbie-Hurder; Karen N Price; Jürg Bernhard; Weixiu Luo; Karin Ribi; Giuseppe Viale; Alan S Coates; Richard D Gelber; Aron Goldhirsch; Prudence A Francis
Journal:  N Engl J Med       Date:  2014-06-01       Impact factor: 91.245

8.  Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93.

Authors:  Marco Colleoni; Shari Gelber; Edda Simoncini; Olivia Pagani; Richard D Gelber; Karen N Price; Monica Castiglione-Gertsch; Alan S Coates; Aron Goldhirsch
Journal:  Ann Oncol       Date:  2007-04-11       Impact factor: 32.976

9.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.

Authors:  John F Forbes; Jack Cuzick; Aman Buzdar; Anthony Howell; Jeffrey S Tobias; Michael Baum
Journal:  Lancet Oncol       Date:  2008-01       Impact factor: 41.316

10.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.

Authors:  C Davies; J Godwin; R Gray; M Clarke; D Cutter; S Darby; P McGale; H C Pan; C Taylor; Y C Wang; M Dowsett; J Ingle; R Peto
Journal:  Lancet       Date:  2011-07-28       Impact factor: 79.321
View more
  4 in total

1.  Arenobufagin induces MCF-7 cell apoptosis by promoting JNK-mediated multisite phosphorylation of Yes-associated protein.

Authors:  Li-Juan Deng; Ming Qi; Qun-Long Peng; Min-Feng Chen; Qi Qi; Jia-Yan Zhang; Nan Yao; Mao-Hua Huang; Xiao-Bo Li; Yin-Hui Peng; Jun-Shan Liu; Deng-Rui Fu; Jia-Xu Chen; Wen-Cai Ye; Dong-Mei Zhang
Journal:  Cancer Cell Int       Date:  2018-12-18       Impact factor: 5.722

Review 2.  Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer.

Authors:  Hsing-Ju Wu; Pei-Yi Chu
Journal:  Int J Mol Sci       Date:  2021-01-10       Impact factor: 5.923

Review 3.  HOXA11 antisense long noncoding RNA (HOXA11-AS): A promising lncRNA in human cancers.

Authors:  Cheng-Wei Lu; Dan-Dan Zhou; Tian Xie; Ji-Long Hao; Om Prakash Pant; Cheng-Bo Lu; Xiu-Fen Liu
Journal:  Cancer Med       Date:  2018-07-10       Impact factor: 4.452

4.  Anti‑cancer effects of fisetin on mammary carcinoma cells via regulation of the PI3K/Akt/mTOR pathway: In vitro and in vivo studies.

Authors:  Xu Sun; Xueman Ma; Qiwei Li; Yong Yang; Xiaolong Xu; Jiaqi Sun; Mingwei Yu; Kexin Cao; Lin Yang; Guowang Yang; Ganlin Zhang; Xiaomin Wang
Journal:  Int J Mol Med       Date:  2018-05-02       Impact factor: 4.101
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.